What is the role of cerebrospinal fluid biomarkers in the workup of Langerhans cell histiocytosis (LCH)?

Updated: Jun 12, 2020
  • Author: Christopher R Shea, MD; Chief Editor: William D James, MD  more...
  • Print

The results of a small Swedish study evaluating LCH patients with known neurodegeneration on MRI suggest that serial monitoring of cerebrospinal fluid biomarkers (including neurofilament light chain [NF-L], Tau, and glial fibrillary acidic protein [GFAp]) may help evaluate disease onset, severity, and response to therapy in patients with neural involvement. [59] However, more robust studies must be performed to evaluate this claim before such tests become common practice.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!